 Home > Active Ingredient News > Immunology News > ARD: EULAR points to consider when analyzing and reporting comparative effectiveness studies using observational data in rheumatology

ARD: EULAR points to consider when analyzing and reporting comparative effectiveness studies using observational data in rheumatology

 Last Update: 2022-08-16
 Source: Internet
 Author: User

Tags

transparent building

sewage treatment plant

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

OBJECTIVE : Comparing treatment effects in observational settings over time is hindered by several major factors, including confounding and dropout bi.

Objectives : Comparing treatment effects in observational settings over time is hindered by several major factors, including confounding and exit bi.

Methods : PtC was developed using a three-step process according to EULAR standard operating procedur.

Methods Methods : PtC was developed using a three-step process according to EULAR standard operating procedur.

Results Results : Three overarching principles and 10 PtCs were developed , specifically addressing potential biases related to withdrawal or confounding by indicatio.

The three principles include :

Treatment efficacy is related to how the treatment performs in a routine clinical setting ;
Inadequacies in observational study data, including confounding and missing data ;
Well-designed and transparent epidemiological and statistical methods increase confidence in observed data resul.

Conclusions : To improve the reliability of the growing number of real-world comparative validity studies in rheumatology, special attention is needed to reduce potential bi.

CONCLUSIONS CONCLUSIONS : To improve the reliability of the growing number of real-world comparative effectiveness studies in rheumatology, special attention is needed to reduce potential bi.

Courvoisier DS, Lauper K, Kedra J , et a.
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatolo.
Annals of the Rheumatic Diseases2022; 81: 780-78 , et al Annals of the Rheumatic Diseases81: Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Top Quality 99.9% Ritlecitinib Tosylate Immunoregulation API & Inflammation Inhibitor

CAS No.: 2192215-81-7

Pharmacy Grade; Food Grade

$200-250/G FOB

β-Alanine107-95-9

CAS No.: 107-95-9

$1-1.1/KG FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.